In addition, some tumor suppressors were identified, such as: ACY1, CDO1, CEBPA, GLS2, MST1, and NR0B2. The prominent feature of the signature associated with ITIH1 expression was the identification of critical negative regulators for LIHC glycolysis, including CYP2A6, CYP3A4, HSD17B13, LECT2, SLC10A1, and SPP2; notably, high expression of CYP3A4, HSD17B13, LECT2, SLC10A1, and SPP2 were associated with favorable outcomes in LIHC patients [15]. Here, GLS2 is linked to neoplasm.